Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 9/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.50 |
| ▸ | MAPKAPK3 | Q16644 | 5/20 | 0.50 |
| ▸ | MAPK6 | Q16659 | 5/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.50 |
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.50 |
| ▸ | ITK | Q08881 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FADS1 | O60427 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20001489 | 0.86 | MAP2K4 (0.48) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL130781 | 0.85 | ITK (0.47) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL5952447 | 0.84 | MAP2K4 (0.60) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL7740374 | 0.83 | MAPT (0.50) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL7978106 | 0.81 | HTR1D (0.41) | MAP2K4SMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL17229303 | 0.81 | MAP2K4 (0.47) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL27750994 | 0.81 | MAP2K4 (0.54) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL10271562 | 0.80 | ITK (0.43) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL11946877 | 0.80 | TTK (0.35) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL182234 | 0.80 | PDPK1 (0.58) | FADS1MAPTHPGDCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE37781-E1 | VIRICIDES, PROTEASE INHIBITOR | DUPONT PHARMACEUTICALS COMPANY | 2002-07-02 | — | — | US | claimed |
| EP-0837855-A4 | METHOD FOR PREPARING N-MONOSUBSTITUTED AND N,N'-DISUBSTITUTED UNSYMMETRICAL CYCLIC UREAS | DU PONT MERCK PHARMA (US) | 1998-09-02 | — | — | EP | claimed |
| EP-0837855-A1 | METHOD FOR PREPARING N-MONOSUBSTITUTED AND N,N'-DISUBSTITUTED UNSYMMETRICAL CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-04-29 | — | — | EP | claimed |
| US-5610294-A | VIRAL TREATMENT | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-03-11 | — | — | US | claimed |
| WO-1997008150-A1 | SUBSTITUTED CYCLIC UREAS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-03-06 | — | — | WO | claimed |
| WO-1996040652-A1 | METHOD FOR PREPARING N-MONOSUBSTITUTED AND N,N'-DISUBSTITUTED UNSYMMETRICAL CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-19 | — | — | WO | claimed |
| US-5532357-A | Method for preparing N-monosubstituted and N,N'-disubstituted unsymmetrical cyclic ureas | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-02 | — | — | US | claimed |
| WO-2021032209-A1 | ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF | 四川海思科制药有限公司 | 2021-02-25 | — | — | WO | disclosed |
| EP-2870150-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3 V BIOSCIENCES INC (US) | 2019-06-19 | — | — | EP | disclosed |
| US-9695166-B2 | Pyrazolopyridine pyrazolopyrimidine and related compounds | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-1029859-A1 | N,N'-Disubstituted unsymmetrical cyclic urea and its use in therapy | Dupont Pharmaceuticals Company (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-0837855-A4 | METHOD FOR PREPARING N-MONOSUBSTITUTED AND N,N'-DISUBSTITUTED UNSYMMETRICAL CYCLIC UREAS | DU PONT MERCK PHARMA (US) | 1998-09-02 | — | — | EP | disclosed |
| US-5763469-A | Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0837855-A1 | METHOD FOR PREPARING N-MONOSUBSTITUTED AND N,N'-DISUBSTITUTED UNSYMMETRICAL CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-04-29 | — | — | EP | disclosed |
| WO-1997008150-A1 | SUBSTITUTED CYCLIC UREAS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-03-06 | — | — | WO | disclosed |
| WO-1996040652-A1 | METHOD FOR PREPARING N-MONOSUBSTITUTED AND N,N'-DISUBSTITUTED UNSYMMETRICAL CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5532357-A | Method for preparing N-monosubstituted and N,N'-disubstituted unsymmetrical cyclic ureas | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | TPMT, DPYD, XDH | MAP2K4 1698/4885MAPK1 1161/4885MAPKAPK3 364/4885 |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | MAP2K4 645/4885MAPK1 251/4885MAPKAPK3 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.